Low-Dose Anti-Thymocyte Globulin Preserves C-Peptide, Reduces HbA1c, and Increases Regulatory to Conventional T-Cell Ratios in New-Onset Type 1 Diabetes: Two-Year Clinical Trial Data-Reference-Cited by-同舟云学术

Low-Dose Anti-Thymocyte Globulin Preserves C-Peptide, Reduces HbA1c, and Increases Regulatory to Conventional T-Cell Ratios in New-Onset Type 1 Diabetes: Two-Year Clinical Trial Data

Published:2019-04-09 Issue:6 Volume:68 Page:1267-1276
ISSN:0012-1797
Container-title:Diabetes
language:en
Short-container-title:Diabetes

Author:

Haller Michael J.^ORCID,Long S. Alice^ORCID,Blanchfield J. Lori,Schatz Desmond A.^ORCID,Skyler Jay S.,Krischer Jeffrey P.^ORCID,Bundy Brian N.,Geyer Susan M.,Warnock Megan V.,Miller Jessica L.,Atkinson Mark A.^ORCID,Becker Dorothy J.,Baidal David A.,DiMeglio Linda A.,Gitelman Stephen E.,Goland Robin,Gottlieb Peter A.,Herold Kevan C.^ORCID,Marks Jennifer B.,Moran Antoinette^ORCID,Rodriguez Henry,Russell William E.,Wilson Darrell M.,Greenbaum Carla J.^ORCID

Funder

National Institutes of Health

National Center for Research Resources

JDRF

American Diabetes Association

Immune Tolerance Network

National Institute of Allergy and Infectious Diseases

The Leona M. and Harry B. Helmsley Charitable Trust

Sanofi

Publisher

American Diabetes Association

Subject